Prasterone

FDA label, Millicent US, Inc., vaginal, effective 2026-07-17. Full label on DailyMed

Patient handout

Looking up MedlinePlus…

From MedlinePlus, U.S. National Library of Medicine

Quoted from the FDA label. Product labels differ by manufacturer and change over time; confirm against the label for the product you are using.

Dosing in kidney impairment

Renal Impairment The effect of renal impairment on the pharmacokinetics of prasterone has not been studied.

Renal Impairment The effect of renal impairment on the pharmacokinetics of prasterone has not been studied.

Dosing in liver impairment

Hepatic Impairment The effect of hepatic impairment on the pharmacokinetics of prasterone has not been studied.

Hepatic Impairment The effect of hepatic impairment on the pharmacokinetics of prasterone has not been studied.

Contraindications

Undiagnosed abnormal genital bleeding: Any postmenopausal woman with undiagnosed, persistent or recurring genital bleeding should be evaluated to determine the cause of the bleeding before consideration of treatment with INTRAROSA. Undiagnosed abnormal genital bleeding. ( 4 )

Supply and cost

Drug shortage status

Loading
Source: FDA Drug Shortages Database via openFDA

Recalls (last 24 months)

Loading
Source: FDA Enforcement Reports via openFDAFDA recalls and safety alerts

Therapeutic equivalence (Orange Book)

Loading
Source: FDA Orange Book data filesSearch the Orange Book

Price ladder

Not the price at the counter
Loading

These are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.

VA Federal Supply ScheduleCMS NADACMedicare Part D plan filesMedicaid State Drug Utilization Data

Calculators for prasterone